Quick Recap
GI & Hepatology System, Protocol 1/13.
1. Definition & Epidemiology
GIB is categorized as UGIB (bleeding proximal to the duodenal ampulla of Vater), small bowel bleeding (ampulla of Vater to ileocecal valve, formerly "obscure GIB"), and LGIB (distal to ileocecal valve) — modern endoscopic/radiographic capability has refined the old proximal/distal-to-ligament-of-Treitz split.
US burden: ~530,855 GIB admissions (2018), 9,548 deaths (2019), ~$302 million in care costs. UGIB mortality stable at 6-12%. 80-90% of UGIB is nonvariceal; incidence of nonvariceal UGIB has DECLINED over time, likely reflecting lower H. pylori prevalence and widespread PPI use.
2. Etiology
Cause | Approx. frequency |
Peptic ulcer disease (gastric/duodenal) | ~50% |
Esophageal/gastric varices | 10-20% |
Gastric erosions/gastritis, stress ulcers | — |
Mallory-Weiss tear | — |
Esophagitis/esophageal ulcers | — |
Vascular (angiodysplasia, Dieulafoy lesion, telangiectasia) | — |
Portal hypertensive gastropathy | — |
Neoplasm (benign/malignant) | — |
Hemobilia, hemosuccus pancreaticus | Rare |
Aortoenteric fistula | Rare but must-not-miss |
3. Immediate Stabilization (ABCDE)
Severity assessment by hemodynamics (before any lab result returns):
- Resting hypotension in a previously normotensive/hypertensive patient -> ~20-25% circulating volume lost — "massive" bleeding
- Postural/orthostatic change (SBP drop >=15 mmHg or HR rise >=20 bpm) without resting hypotension -> 10-20% volume loss
- Neither present -> minor bleeding, <10% volume loss
Airway: intubate for massive UGIB or altered mental status to protect the airway for safe endoscopy — do not attempt endoscopy in an unprotected airway with active/massive bleeding.
Circulation:
- Two large-bore IVs or a central line, urgent crystalloid
- Blood product resuscitation: PRBCs are privileged over other products — correcting coagulopathy/thrombocytopenia is UNNECESSARY in most cases, and excessive FFP/platelet transfusion can worsen portal pressure, itself a bleeding risk factor in variceal disease — avoid reflexive "shotgun" component transfusion
- Restrictive transfusion strategy generally preferred (see Section 12 landmark trial) over liberal transfusion
Checklist:
4. Focused History & Presentation
Melena typically indicates a proximal source but can arise as distally as small bowel/colon. Hematochezia usually suggests LGIB, but ~10% of hematochezia with altered hemodynamics has an UPPER source — brisk UGIB can transit rapidly enough to present as bright red blood per rectum; do not assume LGIB from hematochezia alone in an unstable patient. Known cirrhosis/varices history, anticoagulant/antiplatelet/NSAID use, peptic ulcer history, prior GIB, recent vomiting (Mallory-Weiss), aortic graft history (aortoenteric fistula).
NG tube aspiration: bloody aspirate establishes UGIB (poor prognosis marker without intervention), but absence of bloody aspirate does NOT exclude UGIB. NG lavage may help predict high-risk lesions but does not impact clinical outcome — maintain NG tube only in selected patients, not routinely. Hemoccult testing of NG aspirate/stool has very little value and should NOT be performed.
5. Anticoagulation/Antiplatelet Management
- Vitamin K antagonist reversal: FFP only in rare life-threatening cases when INR is supratherapeutic and PCC unavailable; vitamin K itself has no immediate effect — role limited to permanent anticoagulation discontinuation or slow supratherapeutic INR correction; PCC is FAVORED OVER FFP for supratherapeutic INR correction (more reliable, faster onset), reserved for life-threatening GIB or when massive transfusion avoidance is desired
- DOACs: reversal agents exist but are NOT used routinely given high cost and limited evidence of benefit; reserve DOAC-specific reversal or PCC for life-threatening GIB within 24h of last DOAC dose
- Platelet transfusion is NOT recommended for patients on antiplatelet agents presenting with GIB (mirrors the general critical care principle that platelet transfusion outside specific indications doesn't help and may harm)
- Aspirin for secondary CV prevention: do NOT interrupt for GIB; if held, resume within 24 hours of endoscopic hemostasis
- No role for tranexamic acid in GIB — explicit negative recommendation
- Any anticoagulation reversal decision requires direct input from cardiology/hematology/the managing anticoagulation team
6. Pharmacologic Management — Variceal vs Nonvariceal
Suspected/Confirmed Variceal Bleeding
Octreotide 50mcg IV bolus, then 50mcg/h continuous infusion for 2-5 days — lowers splanchnic/portal venous pressure, slows/stops variceal bleeding; start EARLY on suspicion, before confirmation.
Prophylactic antibiotics: IV ceftriaxone 1g/day x7 days — prevents infectious complications (esp. SBP) and is associated with DECREASED rebleeding risk; give regardless of ascites presence.
Diagnostic paracentesis if ascites present.
Nonvariceal (or Undetermined) UGIB
PPI therapy — suppresses gastric acid (alkaline milieu stabilizes clot, downstages endoscopic lesions, may reduce need for endoscopic therapy):
- IV bolus: omeprazole 40mg q12h (or equivalent)
- IV bolus + infusion (preferred for rapid ongoing bleeding): pantoprazole 80mg bolus, then 8mg/h infusion
- Stable patients without active bleeding: oral double-dose PPI (omeprazole 40mg BID or equivalent) reasonable, at least until endoscopy
- In patients who do NOT undergo endoscopy, double-dose PPI BID reduces rebleeding/surgery need in acute peptic ulcer bleeding
7. ICU Triage Criteria
Admit to ICU: hypotension at presentation; moderate-severe bleeding onset while hospitalized for unrelated illness; ongoing hemodynamic instability despite resuscitation; inadequate hematocrit rise despite transfusion; low initial hematocrit (<25% with cardiopulmonary disease/stroke, <20% otherwise); bright/dark red NG aspirate not clearing with lavage; prolonged PT (>1.2x control); MI/stroke/other systemic complication of blood loss; unstable comorbidity including altered mental status; variceal bleeding; active oozing/spurting/visible vessel on endoscopy.
Regular floor appropriate: stable hemodynamics after resuscitation, mild Hct drop (<5% from baseline, baseline >30%), stable coagulation, coffee-ground aspirate clearing with lavage, no systemic complications, no source found on EGD, nonvariceal source without active bleeding (clean/pigmented base).
Factors predicting poor outcome: age >65, comorbidities (liver disease, COPD, renal failure, CAD, malignancy), variceal bleeding, SBP <100 at presentation, ulcers >3cm, active bleeding at endoscopy, multiple-unit transfusion, onset while hospitalized for unrelated illness, need for emergency surgery.
8. Endoscopy — Timing and Technique
Timing: upper endoscopy within 12 hours for suspected variceal UGIB, within 24 hours for suspected nonvariceal UGIB. Urgent endoscopy for any significant/ongoing bleeding. Hemodynamic normalization should be in progress (not necessarily complete) when endoscopy is performed — do not delay indefinitely for perfect stability.
Pre-procedure optimization: prokinetics (metoclopramide 5-10mg IV or erythromycin 250mg IV) to induce gastric emptying for a cleaner field, reducing repeat-endoscopy need; large-bore double-lumen orogastric lavage in select cases. Routine second-look endoscopy is NOT recommended.
Hemostatic techniques: variceal band ligation, sclerotherapy, glue injection (variceal); epinephrine injection, thermal cautery, hemoclips, sclerosant injection (nonvariceal); newer options: over-the-scope clips, hemostatic powder, endoscopic suturing, esophageal stents.
Endoscopic finding -> rebleeding/mortality risk AFTER treatment (Laine & Peterson):
Finding | Rebleeding risk (treated) | Mortality (treated) |
Clean ulcer base | <5% | 2% |
Flat pigmented spot | 10% (<1% treated) | 3% (<1% treated) |
Adherent clot | 22% (5% treated) | 7% (<3% treated) |
Visible vessel | 43% (15% treated) | 11% (<5% treated) |
Active bleeding | 55% (20% treated) | 11% (<5% treated) |
Observe high-risk peptic ulcer patients requiring endoscopic hemostasis for AT LEAST 72 hours. Test all peptic ulcer patients for H. pylori — eradication reduces recurrent bleeding risk.
9. Refractory Variceal Bleeding — Rescue Therapies
- TIPS (transjugular intrahepatic portosystemic shunt): channel between hepatic vein and intrahepatic portal vein, reduces portal pressure. Indicated for variceal bleeding refractory to endoscopy AND for bleeding gastric varices. "Early TIPS" (within 24-48h of endoscopy) in Child B cirrhosis with visible bleeding at endoscopy, or Child C cirrhosis, reduces rebleeding risk and PROLONGS SURVIVAL based on RCT evidence — a proactive, evidence-supported early-intervention strategy rather than reserving TIPS purely as last-resort rescue. TIPS contraindications: pulmonary hypertension, heart failure, severe encephalopathy, polycystic liver disease, tumor in the shunt path, unrecanalizable portal vein thrombosis.
- BRTO (balloon-occluded retrograde transvenous obliteration): effective for gastric/ectopic varices; splenic vein thrombosis-related gastric varices may require splenectomy instead.
- Balloon tamponade (Sengstaken-Blakemore/Minnesota/Linton-Nachlas tube): TEMPORARY stabilization when endoscopy/TIPS is delayed or unsuccessful, or to bridge transport — patient must be intubated and sedated; efficacy better when combined with pharmacologic therapy; requires soft restraints, traction mechanism, manometer for balloon pressure checks.
- Endoscopic ultrasound-guided embolization: option in select bleeding gastric varices.
- Noncardioselective beta-blockers (propranolol, nadolol, carvedilol): effective for reducing initial/recurrent variceal bleeding risk, but introduce ONLY after acute bleeding is controlled and hemodynamics are stable — not an acute-phase intervention.
10. Surgery
Surgical treatment of GIB has become infrequent in the modern endoscopic/interventional era. Remaining roles: bleeding peptic ulcer refractory to endoscopic/angiographic therapy, bleeding cancer, certain anorectal bleeding, aortoenteric fistula bleeding, or concomitant surgical indications (peritonitis, gangrene, obstruction). Timing of surgical consultation is physician/institution-dependent — involve surgery early in refractory cases rather than only as a final fallback.
11. Organ Support
Blood product resuscitation (PRBC-privileged, restrictive strategy); airway protection for massive bleeding/altered mental status; standard ICU supportive care; nutrition once bleeding controlled.
12. Consultation Matrix
Consultation | Trigger | Timing |
Gastroenterology | All UGIB requiring endoscopy | Immediate, per timing in Section 8 |
Interventional Radiology | TIPS/BRTO candidacy, embolization | Urgent for refractory variceal bleeding |
Surgery | Endoscopy/IR-refractory bleeding, aortoenteric fistula, concomitant surgical pathology | As needed |
Hepatology | Cirrhosis-associated variceal bleeding | Immediate |
13. Monitoring Framework
Serial hemoglobin/hematocrit, continuous hemodynamic monitoring, watch for rebleeding signs (recurrent hematemesis/melena, hemodynamic decline), post-TIPS monitoring for encephalopathy, 72h observation for high-risk endoscopic findings.
14. Complications
Rebleeding (risk stratified by endoscopic finding, Section 8), aspiration during endoscopy if airway unprotected, TIPS-associated hepatic encephalopathy, balloon tamponade complications (esophageal rupture, aspiration — requires intubation/sedation and careful technique), transfusion-related complications, aortoenteric fistula (catastrophic if missed). Prevention: appropriate airway protection before endoscopy, restrictive transfusion strategy, early TIPS in appropriate Child B/C candidates. Rescue: balloon tamponade as bridge, TIPS/BRTO for refractory variceal bleeding, surgery for refractory nonvariceal bleeding.
15. Escalation & De-escalation
Escalate: endoscopic hemostasis failure or rebleeding -> repeat endoscopy, then TIPS/BRTO (variceal) or IR embolization/surgery (nonvariceal).
De-escalate: hemostasis achieved, stable Hct trend, no rebleeding over 72h observation window -> transition to oral PPI/beta-blocker (variceal, once stable), plan H. pylori testing/eradication, arrange outpatient follow-up.
16. ICU Discharge Criteria
Hemodynamically stable off blood products, no rebleeding over the appropriate observation window (72h for high-risk endoscopic findings), oral intake tolerated, anticoagulation resumption plan established with the managing specialty, H. pylori testing sent if peptic ulcer identified, beta-blocker initiated if variceal and stable.
17. Documentation & Medicolegal Checklist
18. Key Guidelines
Laine L, Barkun AN, Saltzman JR, et al. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am J Gastroenterol. 2021;116(5):899-917. Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: international consensus group guideline. Ann Intern Med. 2019;171(11):805-822. Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: 2016 AASLD practice guidance. Hepatology. 2017;65(1):310-335.
19. Landmark Trials
Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368(1):11-21 — established restrictive transfusion strategy (Hb <7 trigger) as superior/non-inferior to liberal transfusion in UGIB, foundational to the PRBC-privileged, non-aggressive component-transfusion approach in Section 3.
20. Controversies
Optimal timing threshold for "early TIPS" application (which Child B patients with visible bleeding truly benefit vs standard endoscopic + pharmacologic management alone) continues to be refined beyond the foundational RCTs. DOAC reversal agent use in GIB remains cost/evidence-limited despite availability — real-world adoption lags behind theoretical benefit. The precise role of NG lavage (diagnostic value without proven outcome impact) means practice varies on whether to place/maintain NG tubes at all in suspected UGIB.
21. References
- Amornsawadwattana S, Gyawali CP. Gastrointestinal Bleeding. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 52).
- Laine L, Barkun AN, Saltzman JR, et al. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am J Gastroenterol. 2021;116(5):899-917.
- Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2019;171(11):805-822.
- Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: 2016 AASLD practice guidance. Hepatology. 2017;65(1):310-335.
- Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368(1):11-21.
- Abraham NS, Barkun AN, Sauer BG, et al. ACG-CAG guideline: management of anticoagulants and antiplatelets during acute GIB. Am J Gastroenterol. 2022;117(4):542-558.
- Laine L, Petersen WL. Bleeding peptic ulcer. N Engl J Med. 1994;331:717-727.